AOD-9604

A failed obesity drug candidate that reappeared on the peptide market. Fragmenting GH did not deliver GH-like fat loss in adequate trials. Treat current marketing as recycling, not a new discovery.

A modified C-terminal fragment of growth hormone, developed to isolate lipolytic effects without the full GH/IGF-1 growth axis. That was the hypothesis. Clinical obesity development did not succeed.

Calzada/Metabolic Pharmaceuticals-era trials in obesity did not meet the bar for approval. Some small body-composition and cartilage papers exist. This is not a hidden success story.

Not FDA-approved. Previously explored as a drug; not on the US market as a medicine. WADA has listed it. Research-chemical sales persist.

A failed obesity drug candidate, not an approved medicine. Research-chemical sales persist. WADA lists GH fragments. Not a compounding success story.

Same four pathways as the Sourcing guide.

None. The development program did not produce a product for a formulary.

Reappeared as a 'safe GH fragment' in fat-loss stacks. That marketing recycles a failed file.

Strand does not list vendors. See the grey market.

Trial-era safety was generally unremarkable, which is not efficacy. Gray-market injectables reintroduce sterility and identity risk. It should not be assumed 'safer than GH' in unsupervised use.

• Obesity trials did not meet the bar for approval — that is evidence of non-success, not a hidden win.
• Grey-market injectables reintroduce sterility and identity risk.
• Anti-doping listing for tested athletes.

• Obesity development

  Metabolic Pharmaceuticals-era AOD-9604 trials did not achieve approval.

• WADA

  GH fragments listed among prohibited agents.